

Ref. No.: QHTL/Sec/SE/2025-26/58

October 15, 2025

The Manager,
Corporate Services,
BSE Limited,
14th floor, P J Towers, Dalal Street,
Mumbai – 400 001
Ref: Security ID: QUICKHEAL
Security Code: 539678

The Manager,
Corporate Services,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: QUICKHEAL
Series: EQ

Subject: Outcome of Board Meeting October 15, 2025.

Dear Sir / Madam,

We wish to inform you that the Board of Directors at its meeting held on October 15, 2025 at the registered office, which commenced at 05:30 PM IST and concluded at 09:53 PM, has approved following:

1. Unaudited Consolidated and Standalone Financial Results of the Company for the Quarter and Half Year ended September 30, 2025.
2. Pursuant to Regulation 33 of SEBI Regulations, we have enclosed herewith Limited Review Report for the unaudited Standalone & Consolidated financial results for the Quarter and Half Year ended September 30, 2025 received from our Statutory Auditors M S K A & Associates, Chartered Accountants.

We also enclose herewith copy of the Press Release being issued in respect of aforesaid financial results and presentation on financial results.

This is for your information and records.

For Quick Heal Technologies Limited

Vikram Dhanani
Compliance Officer

A. Quarterly and Half yearly Financial Results
QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED AND ITS SUBSIDIARIES FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ in Crores, except earnings per share)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		September 30, 2025 Unaudited	June 30, 2025 Unaudited	September 30, 2024 Unaudited	September 30, 2025 Unaudited	September 30, 2024 Unaudited	March 31, 2025 (Audited)
1	Income						
	Revenue from operations	83.52	57.23	73.49	140.75	143.78	279.53
	Other income	4.38	5.75	5.20	10.13	10.26	20.77
	Total income	87.90	62.98	78.69	150.88	154.04	300.30
2	Expenses						
	Cost of material consumed	2.41	0.86	2.01	3.27	3.38	6.10
	Purchase of security software products	-	-	0.45	-	0.45	0.45
	Changes in inventory of security software products	(0.16)	(0.06)	-	(0.22)	-	0.58
	Employee benefits expense	48.58	43.89	47.36	92.47	91.67	185.55
	Finance costs	0.05	0.06	0.05	0.11	0.10	0.22
	Depreciation and amortisation expense	3.28	2.96	3.15	6.24	5.94	12.96
	Other expenses	23.46	22.27	20.60	45.73	42.62	93.44
	Total expenses	77.62	69.98	73.62	147.60	144.16	299.30
3	Profit/ (loss) before tax (1-2)	10.28	(7.00)	5.07	3.28	9.88	1.00
4	Tax expense						
	Current tax	0.71	-	1.01	0.71	2.04	-
	Adjustments of tax relating to earlier periods (Net)	-	-	-	-	-	0.44
	Deferred tax charge/ (benefit)	1.66	(1.49)	(0.09)	0.17	(0.34)	(4.48)
	Total tax expense/ (benefit)	2.37	(1.49)	0.92	0.88	1.70	(4.04)
5	Profit/ (loss) after tax (3-4)	7.91	(5.51)	4.15	2.40	8.18	5.04
6	Other comprehensive income/ (loss) (net of tax)						
	Items that will not be reclassified subsequently to profit or loss :						
	Gain/ (loss) on re-measurement of defined benefit plans	(0.27)	0.22	(0.51)	(0.05)	(0.30)	(0.19)
	Net (loss) or gain on FVOCI instruments	0.01	-	-	0.01	-	(0.17)
	Items that will be reclassified subsequently to profit or loss :						
	Exchange differences on translation of foreign operations	0.06	0.09	0.01	0.15	0.04	0.07
	Total other comprehensive income/ (loss) for the period	(0.20)	0.31	(0.50)	0.11	(0.26)	(0.29)
7	Total comprehensive income/ (loss) (after tax) (5+6)	7.71	(5.20)	3.65	2.51	7.92	4.75
8	Paid-up equity share capital (face value of ₹ 10 each, fully paid up)	54.14	54.02	53.80	54.14	53.80	54.00
9	Other equity excluding revaluation reserves as per balance sheet	-	-	-	-	-	387.48
10	Earnings/ (loss) per share of ₹ 10 each: (not annualised except for the year ended March)						
	a) Basic	1.43	(1.00)	0.77	0.43	1.53	0.94
	b) Diluted	1.42	(1.00)	0.75	0.43	1.49	0.91




QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED AND ITS SUBSIDIARIES FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**Notes to financial results:**

- 1 The unaudited consolidated financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The above financial results for the quarter and half year ended September 30, 2025 have been subjected to limited review by the statutory auditors of the Holding Company and reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at the meeting held on October 15, 2025.
- 2 During the year ended March 31, 2025, the Regional P.F. Commissioner ("RPFC") passed an order under Section 7A & 7Q of the Employees' Provident Funds and Miscellaneous Provisions Act, 1952 ("Act") demanding ₹ 5.01 (including interest of ₹ 2.49) on the grounds that it failed to remit Provident Fund ("PF") on wages for its employees for the period from September 2014 to March 2019 for certain allowances of salary. The Holding Company filed an appeal before the Central Government Industrial Tribunal Cum-Labour Court ("CGIT") challenging the Employees' Provident Fund Organisation's ("EPFO") order along with the application under Section 7O of the Act seeking a waiver from pre-deposit of the alleged Provident Fund Contributions till the final disposal of the Appeal. The CGIT, after hearing the submissions made, passed an Order and directed RPFC, not to proceed with the recovery against the Holding Company on depositing 30% of the total amount assessed. The Holding Company, based on the legal counsel's opinion, is of the view that the claim made by the RPFC is not probable, and accordingly no provision is recorded in the financial results of the period ended September 30, 2025.
- 3 Mr. Bhushan Gokhale has retired as an Independent directors of the Holding Company w.e.f. August 11, 2025.
Ms. Apurva Joshi has retired as an Independent directors of the Holding Company w.e.f. September 23, 2025.
- 4 As at September 30, 2025, the Holding Company has the following subsidiaries :
 - a) Quick Heal Technologies America Inc.
 - b) Seqrite Technologies DMCC.
- 5 The Group is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 6 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune
Date: October 15, 2025



For and on behalf of the Board of Directors


Kailash Katkar
Chairman & Managing Director

DIN No: 00397191

QUICK HEAL TECHNOLOGIES LIMITED		
Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014		
CIN: L72200MH1995PLC091408		
STATEMENT OF CONSOLIDATED UNAUDITED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2025		
	₹ in Crores	
	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)
Assets		
Non-current assets		
(a) Property, plant and equipment	81.00	83.15
(b) Capital work-in-progress	8.83	0.05
(c) Investment Property	34.21	35.01
(d) Intangible assets	0.50	0.72
(e) Right-of-use assets	1.22	0.33
(f) Financial assets		
(i) Investments	7.29	7.28
(ii) Other financial assets	0.78	0.89
(g) Deferred tax assets (net)	7.78	7.94
(h) Income tax assets (net)	20.07	17.20
(i) Other non-current assets	6.63	1.35
	168.31	153.92
Current assets		
(a) Inventories	2.44	2.22
(b) Financial assets		
(i) Investments	178.20	172.01
(ii) Trade receivables	175.85	166.73
(iii) Cash and cash equivalents	6.72	20.84
(iv) Bank balances other than (iii) above	0.12	0.13
(v) Other financial assets	1.79	1.27
(c) Other current assets	10.61	7.92
(d) Assets classified as held for sale	1.29	-
	377.02	371.12
Total assets	545.33	525.04
Equity and liabilities		
Equity		
(a) Equity share capital	54.14	54.00
(b) Share application money pending allotment	0.21	-
(c) Other equity	392.10	387.48
Total equity	446.45	441.48
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	-	0.09
(b) Employee benefit obligations	-	0.74
(c) Other non-current liabilities	9.84	4.02
	9.84	4.85
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	3.48	3.52
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	39.19	31.41
(ii) Other financial liabilities	2.17	1.76
(b) Employee benefit obligations	17.00	18.13
(c) Other current liabilities	27.19	23.88
(d) Income tax liabilities (net)	0.01	0.01
	89.04	78.71
Total liabilities	98.88	83.56
Total equity and liabilities	545.33	525.04



Quick Heal Technologies Limited Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408 CONSOLIDATED CASH FLOW STATEMENT			
	Period ended September 30, 2025	Period ended September 30, 2024	Year ended March 31, 2025
	Unaudited	Unaudited	Audited
A. Cash flow from operating activities			
Profit before tax	3.28	9.88	1.00
Adjustment to reconcile profit before tax to net cash flows:			
Net (gain)/ loss on foreign exchange differences	(0.22)	(0.05)	(0.08)
Exchange difference on translation of foreign operations	0.15	-	0.07
Employee share based payments expense	0.63	4.66	9.95
Interest on lease	0.11	0.10	0.22
Rent equalisation	(0.09)	(0.03)	(0.21)
Depreciation and amortization expense	6.24	5.94	12.96
Interest income	(0.18)	(0.26)	(0.78)
Provision for doubtful debts and advances	7.20	-	3.92
(Profit)/ loss on sale of property, plant and equipment	0.04	(0.03)	(0.13)
Income from Investment Property	(2.91)	(2.60)	(5.49)
Net gain on sale of investment	(0.49)	(1.84)	(2.16)
Unrealised gain on investments	(5.84)	(5.18)	(11.30)
Operating profit before working capital changes	7.92	10.59	7.97
Movements in working capital:			
(Increase)/ decrease in trade receivables	(16.08)	(34.15)	(38.83)
(Increase)/ decrease in inventories	(0.22)	0.01	0.58
(Increase)/ decrease in other financial assets	(0.38)	(0.57)	(0.10)
(Increase)/ decrease in other assets	(7.87)	(0.40)	(0.40)
Increase/ (decrease) in net employee benefit obligations	(1.93)	(3.33)	3.05
Increase/ (decrease) in trade payables	7.74	3.30	(4.95)
Increase/(decrease) in other financial liabilities	(0.16)	(0.30)	(0.10)
Increase/ (decrease) in other current and non-current liabilities	9.13	6.17	11.33
Cash (used in)/ generated from operations	(1.85)	(18.68)	(21.45)
Income taxes paid (net of refund)	(3.58)	(4.37)	(0.85)
Net cash flow (used in)/ generated from operating activities (A)	(5.43)	(23.05)	(22.30)
B. Cash flow from investing activities			
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(13.56)	(7.91)	(14.42)
Proceeds from sale of property, plant and equipment	0.06	0.03	0.34
Purchase of investment in mutual funds	(144.42)	(134.44)	(265.10)
Proceeds from sale of investment in mutual funds	144.56	150.45	289.06
Rental income from investment property	2.91	2.60	5.49
Decrease in Deposits with remaining maturity of more than twelve months	0.12	0.03	0.14
Income interest received	0.04	0.07	0.46
Net cash flow (used in)/ generated from investing activities (B)	(10.29)	10.83	15.97
C. Cash flow from financing activities			
Dividend paid	-	(16.16)	(16.13)
Principal and interest paid on lease liabilities	(0.21)	-	(0.10)
Proceeds from issuance of equity shares (including securities premium) on exercise of employee stock options	1.83	3.63	5.91
Net cash flow (used in)/ generated from financing activities (C)	1.62	(12.53)	(10.32)
Net (Decrease)/ increase in cash and cash equivalents (A+B+C)	(14.10)	(24.75)	(16.65)
Cash and cash equivalents at the beginning of the year	20.84	37.51	37.51
Effect of exchange differences on cash and cash equivalents held in foreign currency	(0.02)	-	(0.02)
Cash and cash equivalents at the end of the period	6.72	12.76	20.84
Components of cash and cash equivalents			
Cash on hand	0.02	-	0.01
Balances with banks			
On current account	5.01	11.15	13.63
On EEFC account	1.69	1.61	1.63
Deposits with original maturity of less than three months	-	-	5.57
Total cash and cash equivalents	6.72	12.76	20.84



A. Quarterly and Half yearly Financial Results

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ in Crores, except earnings per share)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)
1	Income						
	Revenue from operations	83.52	57.23	73.57	140.75	143.86	279.53
	Other income	4.38	5.75	5.21	10.13	10.27	20.72
	Total income	87.90	62.98	78.78	150.88	154.13	300.25
2	Expenses						
	Cost of material consumed	2.44	0.83	2.09	3.27	3.45	6.11
	Purchase of security software products	-	-	0.45	-	0.45	0.45
	Changes in inventory of security software products	(0.16)	(0.06)	-	(0.22)	-	0.58
	Employee benefits expense	48.44	43.82	47.21	92.26	91.38	184.95
	Finance costs	0.05	0.06	0.05	0.11	0.10	0.22
	Depreciation and amortisation expense	3.28	2.96	3.15	6.24	5.94	12.96
	Other expenses	23.41	22.31	20.94	45.72	43.08	93.45
	Total expenses	77.46	69.92	73.89	147.38	144.40	298.72
3	Profit/ (loss) before tax (1-2)	10.44	(6.94)	4.89	3.50	9.73	1.53
4	Tax expense						
	Current tax	0.71	-	1.01	0.71	2.04	-
	Adjustments of tax relating to earlier periods (Net)	-	-	-	-	-	0.44
	Deferred tax charge/ (benefit)	1.66	(1.49)	(0.09)	0.17	(0.34)	(4.48)
	Total tax expense/ (benefit)	2.37	(1.49)	0.92	0.88	1.70	(4.04)
5	Profit/ (loss) after tax (3-4)	8.07	(5.45)	3.97	2.62	8.03	5.57
6	Other comprehensive income/ (loss) (net of tax)						
	Items that will not be reclassified subsequently to profit or loss :						
	Gain/ (loss) on re-measurement of defined benefit plans	(0.27)	0.22	(0.51)	(0.05)	(0.30)	(0.19)
	Net (loss) or gain on FVOCI instruments	0.01	-	-	0.01	-	(0.17)
	Total other comprehensive income/ (loss) for the period	(0.26)	0.22	(0.51)	(0.04)	(0.30)	(0.36)
7	Total comprehensive income/ (loss) (after tax) (5+6)	7.81	(5.23)	3.46	2.58	7.73	5.21
8	Paid-up equity share capital (face value of ₹ 10 each, fully paid up)	54.14	54.02	53.80	54.14	53.80	54.00
9	Other equity excluding revaluation reserves as per balance sheet	-	-	-	-	-	387.84
10	Earnings/ (loss) per share of ₹ 10 each: (not annualised except for the year ended March)						
	a) Basic	1.46	(0.99)	0.74	0.47	1.50	1.04
	b) Diluted	1.45	(0.99)	0.72	0.47	1.46	1.01



QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014


CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**Notes to financial results:**

- 1 The unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The above financial results for the quarter and half year ended September 30, 2025 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on October 15, 2025.
- 2 During the year ended March 31, 2025, the Regional P.F. Commissioner ("RPFC") passed an order under Section 7A & 7Q of the Employees' Provident Funds and Miscellaneous Provisions Act, 1952 ("Act") demanding ₹ 5.01 (including interest of ₹ 2.49) on the grounds that it failed to remit Provident Fund ("PF") on wages for its employees for the period from September 2014 to March 2019 for certain allowances of salary. The Company filed an appeal before the Central Government Industrial Tribunal Cum-Labour Court ("CGIT") challenging the Employees' Provident Fund Organisation's ("EPFO") order along with the application under Section 7O of the Act seeking a waiver from pre-deposit of the alleged Provident Fund Contributions till the final disposal of the Appeal. The CGIT, after hearing the submissions made, passed an Order and directed RPFC, not to proceed with the recovery against the Company on depositing 30% of the total amount assessed. The Company, based on the legal counsel's opinion, is of the view that the claim made by the RPFC is not probable, and accordingly no provision is recorded in the financial results of the period ended September 30, 2025.
- 3 Mr. Bhushan Gokhale has retired as an Independent directors of the Company w.e.f. August 11, 2025.
Ms. Apurva Joshi has retired as an Independent directors of the Company w.e.f. September 23, 2025.
- 4 The Company is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 5 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune

Date: October 15, 2025.



For and on behalf of the Board of Directors

Kailash Katkar
Chairman & Managing Director
DIN No: 00397191

QUICK HEAL TECHNOLOGIES LIMITED Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408		
STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2025		
	₹ in crores	
	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)
Assets		
Non-current assets		
(a) Property, plant and equipment	81.00	83.15
(b) Capital work-in-progress	8.83	0.05
(c) Investment property	34.21	35.01
(d) Intangible assets	0.50	0.72
(e) Right-of-use assets	1.22	0.33
(f) Investments in subsidiaries	0.81	0.81
(g) Financial assets		
(i) Investments	7.29	7.28
(ii) Other financial assets	0.78	0.89
(h) Deferred tax assets (net)	7.78	7.94
(i) Income tax assets (net)	20.07	17.20
(j) Other non-current assets	6.63	1.35
	169.12	154.73
Current assets		
(a) Inventories	2.44	2.22
(b) Financial assets		
(i) Investments	178.20	172.01
(ii) Trade receivables	176.23	170.36
(iii) Cash and cash equivalents	6.08	17.10
(iv) Bank balances other than (iii) above	0.12	0.13
(v) Other financial assets	1.79	1.26
(c) Other current assets	10.60	7.86
(d) Assets classified as held for sale	1.29	-
	376.75	370.94
Total assets	545.87	525.67
Equity and liabilities		
Equity		
(a) Equity share capital	54.14	54.00
(b) Share application money pending allotment	0.21	-
(c) Other equity	392.53	387.84
Total equity	446.88	441.84
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	-	0.09
(b) Employee benefit obligations	-	0.74
(c) Other non-current liabilities	9.84	4.02
	9.84	4.85
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	3.48	3.52
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	39.46	31.84
(ii) Other financial liabilities	2.07	1.71
(b) Employee benefit obligations	17.00	18.11
(c) Other current liabilities	27.13	23.79
(d) Income tax liabilities (net)	0.01	0.01
	89.15	78.98
Total liabilities	98.99	83.83
Total equity and liabilities	545.87	525.67



Quick Heal Technologies Limited

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STANDALONE CASH FLOW STATEMENT

₹ in crores

	Period ended September 30, 2025	Period ended September 30, 2024	Year ended March 31, 2025
	Unaudited	Unaudited	Audited
A. Cash flow from operating activities			
Profit before tax	3.50	9.73	1.53
Adjustment to reconcile profit before tax to net cash flows:			
Net (gain)/ loss on foreign exchange differences	(0.24)	(0.01)	(0.10)
Employee share based payments expense	0.63	4.66	9.95
Interest on lease	0.11	0.10	0.22
Rent equalisation	(0.09)	0.04	(0.21)
Depreciation and amortization expense	6.24	5.94	12.96
Interest income	(0.18)	(0.26)	(0.78)
Provision for doubtful debts and advances	7.05	-	3.27
(Profit)/ loss on sale of property, plant and equipment	0.04	(0.03)	(0.13)
Income from Investment Property	(2.91)	(2.60)	(5.49)
Net gain on sale of investment	(0.49)	(1.84)	(2.16)
Unrealised gain on investments	(5.84)	(5.18)	(11.30)
Operating profit before working capital changes	7.82	10.55	7.76
Movements in working capital:			
(Increase)/ decrease in trade receivables	(12.68)	(35.05)	(41.48)
(Increase)/ decrease in inventories	(0.22)	0.08	0.58
(Increase)/ decrease in other financial assets	(0.39)	(0.57)	(0.10)
(Increase)/ decrease in other assets	(7.92)	(0.53)	(0.44)
Increase/ (decrease) in net employee benefit obligations	(1.91)	(3.33)	3.03
Increase/ (decrease) in trade payables	7.58	3.49	(4.74)
Increase/ (decrease) in other financial liabilities	(0.21)	(0.35)	(0.15)
Increase/ (decrease) in other current and non-current liabilities	9.16	5.94	11.38
Cash (used in)/ generated from operations	1.23	(19.77)	(24.16)
Income taxes paid (net of refund)	(3.58)	(4.37)	(0.85)
Net cash flow (used in)/ generated from operating activities (A)	(2.35)	(24.14)	(25.01)
B. Cash flow from investing activities			
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(13.56)	(7.90)	(14.42)
Proceeds from sale of property, plant and equipment	0.06	-0.03	0.34
Purchase of investment in mutual funds	(144.42)	(134.44)	(265.10)
Proceeds from sale of investment in mutual funds	144.56	150.45	289.06
Rental income from investment property	2.91	2.60	5.49
Decrease in Deposits with remaining maturity of more than twelve months	0.12	0.03	0.14
Income interest received	0.04	0.07	0.46
Net cash flow (used in)/ generated from investing activities (B)	(10.29)	10.84	15.97
C. Cash flow from financing activities			
Dividend paid	-	(16.16)	(16.13)
Principal and interest paid on lease liabilities	(0.21)	-	(0.10)
Proceeds from issuance of equity shares (including securities premium) on exercise of employee stock options	1.83	3.63	5.91
Net cash flow (used in)/ generated from financing activities (C)	1.62	(12.53)	(10.32)
Net (Decrease)/ increase in cash and cash equivalents (A+B+C)	(11.02)	(25.83)	(19.36)
Cash and cash equivalents at the beginning of the year	17.10	36.46	36.46
Cash and cash equivalents at the end of the period	6.08	10.63	17.10
Components of cash and cash equivalents			
Cash on hand	0.02	-	0.01
Balances with banks			
On current account	4.37	9.02	9.89
On EEFC account	1.69	1.61	1.63
Deposits with original maturity of less than three months	-	-	5.57
Total cash and cash equivalents	6.08	10.63	17.10



Quick Heal Technologies Limited Reports Q2 FY26 Results

Pune, 15th October 2025: Quick Heal Technologies Limited, a global provider of cybersecurity solutions, today announced its audited financial results for the quarter and half year ended on September 30, 2025.

Key Financial Highlights:

Particulars (₹ Cr)	Q2 FY25	Q1 FY26	Q2 FY26
Revenue	73.5	57.2	83.5
EBITDA	3.1	(9.7)	9.2
EBITDA Margin	4.2%	-17.0%	11.1%
PAT	4.2	(5.5)	7.9
PAT Margin	5.7%	-9.6%	9.5%

Dr. Kailash Katkar, Chairman and Managing Director of Quick Heal Technologies Limited, commented, *“Q2 FY26 witnessed good performance across both verticals of our business, which is a clear reflection of the resilience and diversification of our cybersecurity portfolio through continued investments in differentiated, AI-led innovations. The consumer business has shown recovery with seasonal tailwinds, while our enterprise vertical continues to gain momentum through innovative solution offerings. This balanced growth across our dual business streams reinforces our commitment to delivering comprehensive cybersecurity solutions that address evolving market needs and positions us well for sustained growth in the future.”*

Ankit Maheshwari, Chief Financial Officer, Quick Heal Technologies Limited, added, *“We are pleased with the revenue growth momentum this quarter. Owing to the stable cost structures, the revenue improvement enabled us to restore healthy margins. Our continued investments in R&D and S&M for market expansion are key tenets for our long-term pivot and have started to show positive traction. We are geared up for the second half of the year for continued shareholder value creation.”*

Key Highlights of Q2 FY26 include:

- MoU signed with BHASHINI, integrating Seqrite’s AI-powered cybersecurity modules into India’s multilingual AI platform to deliver data privacy solution in 22 languages.
- Onboarded the first enterprise customer for the Seqrite Data Privacy Management Platform which helps enterprises achieve and maintain compliance with privacy laws like DPDP Act.

- International revenue continues to grow, driven by new market entries in Southeast Asia and the Middle East.
- Seqrite received the “Cybersecurity Service Provider of the Year” Award at the Times Secure India Summit 2025.
- Quick Heal won “The Leading Cybersecurity Solutions Brand of 2025” at NCN Excellence Awards.

As Quick Heal Technologies Limited moves into second half of the fiscal year, the company remains focused on scaling its AI-led innovations, expanding partner ecosystems, and driving predictable growth. With a healthy order pipeline and a diversified revenue mix, the company is well-positioned to deliver sustainable shareholder value.

About Quick Heal Technologies Limited

Quick Heal Technologies Limited is a leading global cybersecurity solutions provider. Incorporated in 1995 with a registered office in Pune, it offers end-to-end cybersecurity solutions across B2C, B2B, and B2G segments. With its widely recognized brands ‘Quick Heal’ and ‘Seqrite’, the company provides AI-powered, patented technologies that protect endpoints, networks, data, mobility, and cloud environments. Committed to R&D and innovation, Quick Heal Technologies continues to simplify security by delivering best-in-class protection against advanced cyber-threats to millions of customers, enterprises, and government organizations worldwide.



SECURITE

Quick Heal


EARNINGS PRESENTATION Q2 FY26

15th Oct 2025



GLOBAL CYBERSECURITY TRENDS

- Consolidation of security stack
- Investment & adoption of Generative AI in Cybersecurity
- Privacy driven Application & Data Decoupling
- Growing Adoption of Cloud Native Application
- Cybersecurity reskilling
- Organizations continue to accelerate their multiyear Security Service Edge (SSE) and Zero Trust (ZT) journey
- Organizations continue to strengthen their security portfolio with new tools





India Cyber Threat Report: **KEY HIGHLIGHTS**

Bigger spectrum of
detections and endpoints

Over
369.01 million
detections recorded
across **8.44**
Million
endpoints

Averaging **702**
detections
per minute

Behavioral-based
detection

53.73 million
behavior-based detections,
accounted for **14.56%**
of total detections

Significant increase
from **12.5%** in 2023

~12 attacks per
month per
personal end
user device

Primary attack vectors

68%
of attacks originated from
Trojans and Infectors

Cloud detections
contributed

62%
while 38% detections
were on-premise





India Cyber Threat Report:


KEY HIGHLIGHTS

Contd.

Geographical Hotspots

Telangana 15.03% of detections		Tamil Nadu 12% of detections
Surat 14.6% of detections	Bengaluru 12% of detections	Jaipur 11.72% of detections

Top-most targeted industries



Malware and Ransomware incidents





OUR PURPOSE

Innovate to “simplify”
securing digital experience



Innovate

Focus on grassroot research and adoption of new tech



Simplify

Ease of manageability & operations for the end customers



Secure

Getting the Job Done: Staying one step ahead of the threat actors to protect our customers



Our **JOURNEY** so far

- **1993-96**
Protected early Generations of PCs
- **1996-00**
Secured PCs, Network & Emails
- **2001-05**
Ensured a safe digital experience for Individuals, Businesses and Government Organizations
- **2006-10**
Threat protection for Smart Phones and Tablets



- **2011-16**
Global Footprint, Foray into enterprise Segment with SEQRITE, & listed on BSE & NSE
- **2017-19**
Protecting Data, Transactions & Cloud transitions
- **2020-23**
Protecting Data, Transactions & Cloud transitions
- **2023-25**
 - CSMA Product Stack
 - Leadership Strengthening
 - India Cyber Threat Report
 - Brand Refresh
 - Anti Fraud Launch
 - SIA Launch
 - International Expansion



THIS IS US



Pioneer of
cybersecurity
in India



1st Listed
Cybersecurity
company in India



Market
Leader
in India



Collaborators with
US bodies
NIST & AISIC



Protecting
9 Million
Active Devices



Patents



Presence in **70+**
countries



~1000
Cybersecurity
Professionals



Protecting Critical
Infrastructure of
India



Proud Owners of **Seqrite Labs**:
Largest in the country



Dr. Kailash Katkar
Managing Director

A Visionary Founder and Leader, a Born Entrepreneur, and an Exemplary Trailblazer, he has transformed Quick Heal into a beacon of success and innovation in the Cybersecurity industry. His business acumen has consistently driven Remarkable financial performance, customer satisfaction, market leadership making Quick Heal & SEQRITE the preferred choice for customers globally.



Dr. Sanjay Katkar
Joint Managing Director

Co-Founder of Quick Heal Technologies Limited, Joint Force, and Technology Powerhouse behind the company's journey. An unmatched Cybertech Mastermind, who is relentlessly shaping the company's global technology strategy and driving core research and development while pursuing product innovation to fortify cyber security.

Founded By The
VISIONARIES



Led By The **INDUSTRY EXPERTS**



Ajit Zanjad
VP & Head of Delivery



Ankit Maheshwari
Chief Financial Officer



Anupama Katkar
Chief of Operational
Excellence



Ashish Pradhan
Chief Technology Officer



Ashish Kadam
Director, Government Business



Deepak Mishra
Co-Head, Retail Sales



Jagannath Patnaik
Co-Head, Retail Sales



Dr. Lalit Mohan
Chief Product Officer



Samuel Sathayjith
Senior VP, Enterprise Sales



Sangamesh S
Head of Secrite Labs



Sudhanshu Tripathi
Chief Marketing Officer



Swapna Sangari
VP, People & Culture



OUR STRATEGY & WAY FORWARD



Expanding Across **3 LEVERS**

Geographic Reach

*Setting up a strong foot in Indian Market
Strategic Expansion in select focused geographies*

Large Customers


*Moving up the customer segments as the solutions mature
Niche Solutions specifically targeted to Large Enterprises (SDP, SMAP, STI)*

Product Stack:

Holistic cybersecurity stack for better protection and increased wallet share



Seqrite **SOLUTION STACK**




An approach to simplify cybersecurity by integrating security solutions from a single vendor




EXPANDING

Serviceable Operatable Market



Levers of SOM Growth



Source: Market Research & Company Estimates



Our **RIGHT TO WIN**

- ⦿ Largest Cybersecurity Lab in India with unique telemetry
- ⦿ Holistic platformised cybersecurity solution
- ⦿ Simple Integrated Architecture
- ⦿ Solving unique value propositions & use cases (E.g.: On prem & cloud)
- ⦿ Best in class support offerings
- ⦿ Adoption of the new age tech in our stack
- ⦿ Make in India
- ⦿ Strong Partner Network across the country
- ⦿ Proximity to the customers in India





AWARDS & RECOGNITIONS

Quick Heal is certified as one of the safest for browsing & banking by AVLab, Poland



Quick Heal is certified the "Product of the year" by AVLab, Poland



Seqrite Endpoint Protection for Best Performance by AV-Test



Seqrite Endpoint Protection Achieves AV-TEST Approved – Top Product Corporate Endpoint Protection





Q2/H1 FY26: **BUSINESS HIGHLIGHTS**



Business **HIGHLIGHTS**

- First Order received for Seqrite Data Privacy
- Growth in Retail business
- Order Book: INR 27+ Cr
- International Revenue continues the positive trend
- Deferred Revenue: INR 17.2 Cr
- Government Business Momentum picking up





Q2 FY26:

PERFORMANCE HIGHLIGHTS

₹ 83.5 Cr

Net Revenue
13.6% YoY

₹ 9.2 Cr

EBITDA
200.7% YoY

₹ 7.9 Cr

PAT
90.6% YoY

₹ 1.4

Diluted EPS
89.6% YoY

₹ 36.9 Cr *

Enterprise Revenue
30.0% YoY

₹ 59.5 Cr *

Consumer Revenue
8.3% YoY

*Based on gross revenues excluding deferred revenue, before adjusting for sales incentives



H1 FY26:

PERFORMANCE HIGHLIGHTS

₹ 140.8 Cr

Net Revenue
-2.1% YoY

₹ (0.5) Cr

EBITDA
-108.8% YoY

₹ 2.4 Cr

PAT
-70.7% YoY

₹ 0.43

Diluted EPS
-71.0% YoY


₹ 68.6 Cr *

Enterprise Revenue
12.8% YoY


₹ 91.2 Cr *

Consumer Revenue
-7.7% YoY


*Based on gross revenues excluding deferred revenue, before adjusting for sales incentives




Deconstructing **CURRENT BUSINESS**



FY 2021



FY 2025



H1 FY 2026


Enterprise

Consumer




Enterprise Business


CLOUD & NON-CLOUD



FY 2024



FY 2025




H1 FY 2026





Seqrite:

ENTERPRISE ARM OF QUICK HEAL





Enterprise MARKETING CAMPAIGNS



Seqrite participated in the **Times Secure India Summit 2025**



Seqrite **SMB Partner Connect 2025**, covered Pune, Mumbai, Chennai, Ahmedabad and Delhi



Customer and Partner Event at Bangalore




Seqrite published an in-depth Cyber Threat Landscape Analysis on **Operation Sindoor** amid the India-Pakistan conflict.



Seqrite participated in India's largest **Urban Co-operative Banks Summit 2025**



Market Leader: **CONSUMER ANTIVIRUS BUSINESS**




- 30 years into existence
- Market leadership with over 30% in the Indian market
- Robust Sales & Distribution network in India

Our Approach:


- Launched **AntiFraud.AI** to tackle the financial frauds
- Focus towards maintaining our market share in AV segment
- Drive consumer awareness in the geography in cybersecurity specific domain




Scaling **REGIONAL RELEVANCE** with Consumer Impact & Partner Synergy



Spreading Consumer Awareness



Digital-first, partner-led festive activations



360° Hyper-Local Campaign



'Freedom campaign'



CSR Update



Total Outreach **68 Lacs+**

Total States Covered **10**

Maharashtra, Karnataka, Gujarat, West Bengal, Chhattisgarh, Uttar Pradesh, Assam, Punjab, Jammu & Kashmir, Madhya Pradesh



Q2/H1 FY26: **FINANCIAL HIGHLIGHTS**



Consolidated P&L

SECURE | Quick Heal

PARTICULARS (In Cr)	Q2 FY25	Q1 FY26	Q2 FY26
Revenue	73.5	57.2	83.5
Direct Cost	2.7	0.9	2.6
Gross Profit	70.8	56.4	81.0
Gross Margin	96.3%	98.5%	96.9%
Operating Cost			
Research and Development	34.0	31.3	32.9
Sales and Marketing	20.2	21.1	22.5
General Administration	13.5	13.6	16.3
Total Expenditure	67.7	66.1	71.7
EBITDA	3.1	(9.7)	9.2
EBITDA %	4.2%	-17.0%	11.1%
Depreciation	3.2	3.0	3.3
EBIT	(0.1)	(12.7)	6.0
Other Income	5.2	5.8	4.4
Finance Cost	(0.1)	(0.1)	(0.1)
Profit Before Tax (PBT)	5.1	(7.0)	10.3
Tax	0.9	(1.5)	2.4
Profit After Tax (PAT)	4.2	(5.5)	7.9
PAT Margin	5.7%	-9.6%	9.5%

H1 FY25	H1 FY26
143.8	140.8
4.3	3.5
139.5	137.3
97.0%	97.5%
68.5	64.2
39.2	43.6
26.2	30.0
133.8	137.8
5.7	(0.5)
3.9%	-0.4%
5.9	6.2
(0.3)	(6.7)
10.3	10.1
(0.1)	(0.1)
9.9	3.3
1.7	0.9
8.2	2.4
5.7%	1.7%


EQUITY AND LIABILITIES (In Cr)	Mar 31, 2025	Sep 30, 2025
Equity		
Equity Share Capital	54.0	54.1
Share application money pending allotment	-	0.2
Reserves and Surplus	387.5	392.1
Total Shareholder Funds	441.5	446.5
Non-Current Liabilities		
Net employee defined benefit liabilities	0.7	0.0
Other Non Current Liabilities	4.2	9.8
Total Non-Current Liabilities	4.9	9.8
Current Liabilities:		
Trade and Other Payables	34.9	42.7
Other Financial Liabilities	1.8	2.2
Other Current Liabilities	23.9	27.2
Employee Benefit Obligations	18.1	17.0
Income tax liabilities (Net)	0.0	0.0
Total Current Liabilities	78.7	89.0
Total Equity & Liabilities	525.0	545.3

ASSETS (In Cr)	Mar 31, 2025	Sep 30, 2025
Non-Current Assets:		
Property, plant and equipment	83.2	81.0
Capital work-in-progress	0.1	8.8
Intangible assets	0.7	0.5
Investment Property	35.0	34.2
Right-of-use assets	0.3	1.2
Non-current financial assets		
Investments in MF, Tax-Free Bonds & others	7.3	7.3
Other Financial Asset	0.9	0.8
Deferred tax assets (net)	7.9	7.8
Income tax assets (net)	17.2	20.1
Other Non Current assets	1.4	6.6
Total Non-Current Assets	153.9	168.3
Current assets:		
Inventories	2.2	2.4
Investment in Mutual Fund	172.0	178.2
Trade and other receivables	166.7	175.9
Cash and Cash Equivalents	20.8	6.7
Bank Balance other than cash & cash equivalents	0.1	0.1
Other Financial Assets	1.3	1.8
Other Current Assets	7.9	10.6
Assets classified as held for sale	-	1.3
Total Current Assets	371.1	377.0
Total Assets	525.0	545.3




Capital Market Data

Shareholding Pattern (as on 30th September 2025)



Stock Market Performance (as on 30th September 2025)



Price Data (as of 30th September 2025)

Face Value	10.00
Market Price	301.70
52 Week H/L	825.90/252.00
Market Cap (INR Mn)	16,335.39
Equity Shares Outstanding (Mn)	54.14
1 Year Avg. Trading Volume ('000)	348.11
1 Year Avg. Net Turnover (Mn)	149.03



DISCLAIMER

For further details, please feel free to contact our Investor Relations Representatives:



Anuj Sonpal
Valorem Advisors
Email: quickheal@valoremadvisors.com
Tel: +91-22-4903 9500

Investor Relations Officer

Deepak Kumar
Deepak.Kumar01@quickheal.com

Company Secretary

Sarang H Deshpande
cs@quickheal.com
+91-20-66813232

CIN No: L72200MH1995PLC091408
www.quickheal.co.in

Quick Heal Technologies Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward-looking statements" based on the currently held beliefs and assumptions of the management of Quick Heal Technologies Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results to differ materially from the results, financial condition, performance, or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment, and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties, and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations, or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration therefrom.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness, and reasonableness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.



SECURITE | Quick Heal

Thank You

Independent Auditor's Review Report on Consolidated Unaudited Financial Results of Quick Heal Technologies Limited for the quarter and year to date September 30, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Quick Heal Technologies Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Quick Heal Technologies Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2025 and the year to-date results for the period from April 01, 2025 to September 30, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Quick Heal Technologies America Inc.	Wholly owned subsidiary
2	Seqrite Technologies DMCC	Wholly owned subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSKA & Associates

Chartered Accountants

6. The Statement includes the interim financial information of two subsidiaries which are not subject to review, whose interim financial information reflects total assets of Rs. 4.40 crores as at September 30, 2025 and total revenue of Rs. 0.78 crores and Rs. 1.98 crores, total net profit after tax and total comprehensive income of Rs. 0.02 crores and Rs. 0.04 crores for the quarter ended September 30, 2025, and for the period from April 01, 2025 to September 30, 2025, respectively, and cash flows (net) of Rs. (3.19) crores for the period from April 01, 2025 to September 30, 2025, as considered in the Statement. This interim financial information has been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

Shraddha D Khivasara
Partner

Membership No.: 134285

UDIN: 25134285BMNT6G1962



Place: Pune

Date: October 15, 2025

Independent Auditor's Review Report on Standalone Unaudited Financial Results of Quick Heal Technologies Limited for the quarter and year to date September 30, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of Quick Heal Technologies Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Quick Heal Technologies Limited (hereinafter referred to as 'the Company') for the quarter ended September 30, 2025 and the year to-date results for the period from April 01, 2025 to September 30, 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

Shraddha D Khivasara
Partner
Membership No.: 134285
UDIN: 25134285BMNTGH3331



Place: Pune
Date: October 15, 2025